2020 25:951–64.Ĭathomas F, Bevilacqua L, Ramakrishnan A, Kronman H, Costi S, Schneider M, et al. MiR-218: a molecular switch and potential biomarker of susceptibility to stress. Torres-Berrío A, Nouel D, Cuesta S, Parise EM, Restrepo-Lozano JM, Larochelle P, et al. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. 2017 8:15497.īaudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Lopez JP, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R, et al. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. 2018 23:69.įan HM, Sun XY, Guo W, Zhong AF, Niu W, Zhao L, et al. Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202. Gheysarzadeh A, Sadeghifard N, Afraidooni L, Pooyan F, Mofid MR, Valadbeigi H, et al. Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Van den Berg MMJ, Krauskopf J, Ramaekers JG, Kleinjans JCS, Prickaerts J, Briedé JJ. Determining the role of microRNAs in psychiatric disorders. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Antidepressant effects of ketamine in depressed patients.
2018 84:272–88.īerman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Treatment resistant depression: a multi-scale, systems biology approach. 2009 60:1439–45.Īkil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, et al.
Media center master download missing episodes gone trial#
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. These findings identify miR-144-3p as a novel target for diagnosis of MDD as well as for antidepressant treatment, and enhance our understanding of epigenetic processes associated with depression.įava M, Kendler KS.
RNA-sequencing analysis of blood after such miR-144-3p knockdown revealed a blunted transcriptional stress signature as well. Lastly, we demonstrate that systemic knockdown of miR-144-3p, via subcutaneous administration of a specific antagomir, is sufficient to reduce the depression-related phenotype in stress-susceptible mice. We identified the red blood cell-specific miR-144-3p as a candidate biomarker to aid depression diagnosis and predict ketamine treatment response in stress-susceptible mice and MDD patients. Furthermore, ketamine treatment was more effective than imipramine at re-establishing baseline miRNA expression levels, but only in mice that responded behaviorally to the drug. We observed robust differences in blood miRNA signatures between stress-resilient and stress-susceptible mice after an incubation period, but not immediately after exposure to the stress. We profiled the expression levels of circulating blood miRNAs from mice that were collected before and after exposure to chronic social defeat stress (CSDS), an extensively validated mouse model used to study depression, as well as after either repeated imipramine or single-dose ketamine treatment.
The present study explored the potential use of miRNAs as biomarkers for MDD and its treatment. MicroRNAs (miRNAs) are short non-coding RNAs, which are detected in body fluids that have emerged as potential biomarkers of many disease conditions. There is an urgent need for objective biomarkers to diagnose this highly heterogeneous syndrome, assign treatment, and evaluate treatment response and prognosis. Major depressive disorder (MDD) is the leading cause of disability worldwide.
0 kommentar(er)
